Topics

Nordic Nanovector: New preclinical Data Offer Insights Into Enhancing Betalutin-Based Therapies in NHL

01:19 EST 4 Dec 2019 | FinanzNachrichten

OSLO, Norway, Dec. 4, 2019 /PRNewswire/ -- Nordic Nanovector ASA (OSE: NANO) announces that new data from preclinical studies investigating the effect of Betalutin (177Lu-lilotomab satetraxetan) o...

Original Article: Nordic Nanovector: New preclinical Data Offer Insights Into Enhancing Betalutin-Based Therapies in NHL

NEXT ARTICLE

More From BioPortfolio on "Nordic Nanovector: New preclinical Data Offer Insights Into Enhancing Betalutin-Based Therapies in NHL"

Quick Search